Analysis on reasons for discontinuations of sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus in real-world practices in Taiwan

被引：0
|
作者：
Lin, Yi-Han [1 ]
Shao, Shih-Chieh [1 ,2 ]
Chan, Yuk-Ying [3 ]
Chen, Hui-Yu [1 ]
Yang, Yea-Huei Kao [2 ]
Lai, Edward Chia-Cheng [2 ,4 ]
机构：
[1] Chang Gung Mem Hosp, Keelung, Taiwan
[2] Natl Cheng Kung Univ, Tainan, Taiwan
[3] Chang Gung Mem Hosp, Taoyuan, Taiwan
[4] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
88
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [21] Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
    Dandona, Paresh
    Chaudhuri, Ajay
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [22] Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
    Kim, Young-Gun
    Han, Seung Jin
    Kim, Dae Jung
    Lee, Kwan-Woo
    Kim, Hae Jin
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [23] Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
    Young-Gun Kim
    Seung Jin Han
    Dae Jung Kim
    Kwan-Woo Lee
    Hae Jin Kim
    Cardiovascular Diabetology, 17
  • [24] Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    Desai, Mehul
    Yavin, Yshai
    Balis, Dainius
    Sun, Don
    Xie, John
    Canovatchel, William
    Rosenthal, Norm
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 897 - 900
  • [25] Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
    Blevins, Thomas C.
    Farooki, Azeez
    POSTGRADUATE MEDICINE, 2017, 129 (01) : 159 - 168
  • [26] Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
    Sriphrapradang, Chutintorn
    Thewjitcharoen, Yotsapon
    Buranapin, Supawan
    Sawanyawisuth, Kittisak
    Yenseung, Nalin
    Ubonchareon, Wisawa
    Limpijankit, Laddawan
    Himathongkam, Thep
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1601 - 1610
  • [27] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
    Whalen, Karen
    Miller, Shannon
    St Onge, Erin
    CLINICAL THERAPEUTICS, 2015, 37 (06) : 1150 - 1166
  • [28] Acute renal outcomes with sodium glucose co-transporter 2 inhibitors: real world data analysis
    Cohen, C. Melzer
    Cahn, A.
    Pollack, R.
    Shalev, V.
    Chodick, G.
    DIABETOLOGIA, 2018, 61 : S301 - S302
  • [29] Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
    Mikhail, Nasser
    WORLD JOURNAL OF DIABETES, 2014, 5 (06): : 854 - 859
  • [30] Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Fractures among Patients with Type 2 Diabetes
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 23 - 23
12345